On November 1st, the U.S. Food and Drug Administration (FDA) published a press release addressing warning letters issued to four companies. The warning letters, sent to companies marketing cannabidiol (CBD) products with therapeutic claims, cites unsubstantiated claims about their products’ ability to treat or cure cancer and other diseases. A snippet of the warning letter issued to Greenroads According to …
Colorado To Begin Requiring Potency Testing For Medical Infused Products
After a delay due to their proficiency testing program roll out, the Colorado Marijuana Enforcement Division (MED) will now require all medical infused products and concentrates be tested for potency and homogeneity, starting November 1st, 2017. After November 1st, all production batches of concentrates from medical product manufacturers will need to have a potency test before being sold, transferred or …